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ABSTRACT
DNA nonhomologous end-joining (NHEJ) and homo-
logous recombination are two distinct pathways
of DNA double-strand break repair in mammalian
cells. Biochemical and genetic studies showed that
DNA ends can also be joined via microhomology-
mediated end joining (MHEJ), especially when pro-
teins responsible for NHEJ, such as Ku, are reduced
or absent. While it has been known that
Ku-dependent NHEJ requires DNA ligase IV, it is
unclear which DNA ligase(s) is required for
Ku-independent MHEJ. In this study, we used a
cell-free assay to determine the roles of DNA ligases
I, III and IV in MHEJ and NHEJ. We found that siRNA
mediated down-regulation of DNA ligase I or ligase
III in human HTD114 cells led to impaired end joining
that was mediated by 2-, 3- or 10-bp microhomology.
In addition, nuclear extract from human fibroblasts
harboring a mutation in DNA ligase I displayed
reduced MHEJ activity. Furthermore, treatment of
HTD114 nuclear extracts with an antibody against
DNA ligase I or III also significantly reduced MHEJ.
These data indicate that DNA ligases I and III are
required in MHEJ. DNA ligase IV, on the contrary, is
not required in MHEJ but facilitates Ku-dependent
NHEJ. Therefore, MHEJ and NHEJ require different
DNA ligases.
DNA double-strand breaks (DSBs) are the most serious
form of DNA damage and a single unrepaired DSB can
lead to cell death (1). In mammalian cells, there are at least
two enzymatically distinct pathways for the repair of
DSBs, homologous recombination (HR) and nonhomo-
logous end joining (NHEJ). HR uses a homologous
template (most frequently the sister chromatid) to carry
out DSB repair, whereas NHEJ joins two ends without
the requirement for extensive homology. Proteins known
to be involved in NHEJ include DNA-PKCS (the catalytic
subunit of DNA-dependent protein kinase), Ku70/
Ku80 heterodimer, XRCC4 (X-ray Cross Complementing
factor 4), and DNA ligase IV (2,3). However, DNA ends
can also be joined via microhomologous sequences ﬂank-
ing the break point, especially when proteins responsible
for NHEJ, such as Ku, are absent or limiting in mam-
malian cells (4–13). Microhomology-mediated end joining
(MHEJ) is always accompanied by a deletion that spans
one of the two homologous sequences and the intervening
sequence, if any, and thus is a mutagenic repair pathway.
Indeed, microhomologies were observed at deletion break
points in the HPRT gene in primary human ﬁbroblasts
(14) and in the Aprt gene in hamster cells (15). Further-
more, translocations mediated by MHEJ were frequently
detected in pre-B cell lymphomas in mouse models (16).
Little is known about the factors involved in MHEJ,
but it can be assumed that the MHEJ pathway may
consist of a series of steps, culminating in the sealing of
DNA nicks by the action of a DNA ligase. DNA ligases
catalyze the joining of nicked DNA in DNA replication,
recombination and repair (17). Eukaryotic cells encode
three well-characterized ATP-dependent DNA ligases,
DNA ligases I, III and IV, each specializing in distinct
pathways of DNA repair and replication (18). Although
these DNA ligases vary in sequence and size, sequence and
structural analyses have shown that they contain a
common catalytic core (18). While the central core of
the enzyme carries out the catalytic function of sealing
nicked DNA, other domains may determine the speciﬁcity
of the various ligases in diﬀerent DNA metabolic
reactions, e.g. by targeting ligases to diﬀerent parts of
the nucleus or by mediating interactions with diﬀerent
proteins. DNA ligase I is involved in at least two distinct
processes within the nucleus: the joining of Okazaki
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newly synthesized patch during base excision repair (BER)
(17). DNA ligase I is recruited to sites of DNA replication
by its interaction with proliferating cell nuclear antigen
(PCNA) (19,20). It has been shown that the loss of its
PCNA binding activity severely compromised the ability
of DNA ligase I to join Okazaki fragments, and to parti-
cipate in long-patch BER (21). Two isoforms of DNA
ligase III resulting from alternately spliced mRNA
variants have been characterized (22). Ligase IIIa is
ubiquitously distributed, whereas ligase IIIb has been
detected only in testes, where it is believed to play a role in
recombination during meiotic prophase (22). DNA ligase
IIIa interacts with XRCC1 (X-ray Cross Complement-
ing factor 1) via its carboxy-terminal BRCT (BRCA
C-terminal) domains and functions in BER (23). DNA
ligase IV is distinct from other DNA ligases in that it
possesses two tandem C-terminal BRCT domains (18).
This protein forms a complex with XRCC4, which
appears to stabilize (24) and stimulate the overall activity
of ligase IV (25). This complex further interacts with
DNA-PKCS and the Ku70/Ku80 heterodimer to function
in NHEJ (26).
Though many studies have revealed the role of DNA
ligases in DNA repair pathways, such as NHEJ and BER,
a systematic study of these ligases in the MHEJ pathway
has been lacking. We recently developed a cell-free assay,
with which factors modulating two end-joining pathways,
i.e. Ku-dependent NHEJ and MHEJ, can be evaluated (9).
We previously showed that Ku and histone H1 facilitate
error-free NHEJ and inhibit MHEJ, and that FEN-1 is
involved in MHEJ. In the present study, we have deter-
mined the roles of DNA ligases I, III and IV in these end-
joining pathways. We found that while DNA ligase IV is
required to join DNA ends in the Ku-dependent NHEJ
pathway, DNA ligase I and ligase III are required in
MHEJ.
MATERIALS AND METHODS
Cells and cell culture
Human cell line HTD114 was grown in DMEM contain-
ing 10% fetal bovine serum (FBS). The DNA ligase
I-deﬁcient human primary ﬁbroblast cell line, GM16096,
and the DNA ligase IV-deﬁcient human primary ﬁbro-
blast cell line, GM16088, were obtained from the NIGMS
Human Genetic Mutant Cell Repository (Camden, NJ,
USA), and were grown in Eagle’s MEM with Earle’s salts
supplemented with 1  concentration of MEM nonessen-
tial amino acids, 2mM glutamine and 10% FBS. WI38
normal diploid human ﬁbroblasts were purchased from
the American Type Culture Collection (Manassas, VA,
USA) and grown in DMEM containing 10% FBS.
RNA interference
Twenty-one nucleotide RNA duplexes (most of them have
a3 0-deoxy thymidine overhang) were purchased from
Ambion, Inc. (Austin, TX, USA). The RNA sequences
were as follows: DNA ligase I, siRNA121249, sense,
50-GGC AUG AUC CUG AAG CAG Att-30, antisense,
50-UCU GCU UCA GGA UCA UGC Ctt-30; DNA ligase
III, siRNA121668, sense, 50-CCA CAA AAA AAA UCG
AGG Att-30, antisense, 50-UCC UCG AUU UUU UUU
GUG Gtg-30; siRNA121372, sense, 50-CGA CCU UUU
AGA CUC AAU Utt-30, antisense, 50-AAU UGA GUC
UAA AAG GUC Gtt-30. A nonsilencing siRNA duplex
(sense, 50-UUC UCC GAA CGU GUC ACG Utt-30,
antisense, 50-ACG UGA CAC GUU CGG AGA Att-30)
(Qiagen, Valancia, CA, USA) was used as a nonsilencing
control. Each siRNA (20nM) was transfected into
HTD114 cells with siPORT Amine reagent (Ambion,
Inc.). Forty-eight hours after transfection, total RNA and
nuclear proteins were extracted.
Real-time PCR forquantification ofgene expression
Total RNA from cells was puriﬁed using RNeasy kits
(Qiagen) and reverse transcribed using the Taqman
Reverse Transcription Reagent kit (Applied Biosystems,
Foster City, CA, USA). The expression of DNA ligase I,
III and IV genes was measured with a quantitative real
time PCR assay as previously reported (27). Expression
levels were calculated as a ratio of the mRNA level for a
given gene relative to the mRNA level for glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) in the same cDNA
sample. Primer sequences are: Lig1-1F, 50-GAA TTC
TGA CGC CAA CAT GCA-30, Lig1-1R, 50-CCG TCT
CTC TGC TGC TAT TGG A-30; Lig3-1F, 50-GAT CAC
GTG CCA CCT ACC TTG T-30, Lig3-1R, 50-GGC ATA
GTC CAC ACA GAA CCG T-30; Lig4-F, 50-CAC CTT
GCG TTT TCC ACG AA-30, Lig4-R, 50-CAG ATG CCT
TCC CCC TAA GTT G-30. To determine whether or not
a certain ligase siRNA treatment could also knock down
other nontargeted ligases, we measured the expression
levels of all DNA ligases in all collected RNA samples.
For each RNA sample, the real-time PCR was performed
in triplicate.
Nuclear extractpreparation
Cells were harvested and washed with ice-cold phosphate
buﬀered saline (PBS). Nuclear protein extracts were
prepared as described (9,28). Protein concentration was
determined by the Bradford assay (29).
Immunoblotting
Equivalent amount of nuclear extracts were separated
with SDS–PAGE gels and transferred onto polyvinylidene
diﬂuoride membranes. Membranes were blocked at room
temperature for 30min in blocking buﬀer [3% nonfat dry
milk in PBS containing 0.1% Tween 20 (T-PBS)] and
incubated at 48C overnight with primary antibody diluted
in blocking buﬀer. After ﬁve washes with T-PBS,
membranes were incubated at room temperature for 1h
with secondary antibody diluted in blocking buﬀer.
Immunoblots were visualized by enhanced chemilumines-
cence. Primary antibodies used in this study were: mouse
anti-DNA ligase I (Novus, Biologicals, Inc., Littleton,
CO, USA), mouse anti-DNA ligase III (Novus,
Biologicals, Inc.), goat anti-DNA ligase IV (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) and rabbit
anti-b-actin (Abcam, Cambridge, MA, USA).
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The construction of linear end-joining substrates with a
10-bp microhomology at both ends (pUC18PD1/4) was
described by Liang et al. (9). After cleavage with the
restriction enzymes Eco47III and EcoRV, the 2.7-kb linear
DNA possesses a 10-bp direct repeat (ATCCTACAGC)
at both ends (Figure 1A). Linear end-joining substrates
with a 2- or 3-bp microhomology at both ends were also
constructed. For the pUC18-2-bp-repeat substrates, a
fragment, which was generated by annealing oligonucleo-
tides (2-bp-repeat-F, 50-AGC TTC GAA TCC GTT CGA
CAG AGG TCT-30, and 2-bp-repeat-R, 50-CTA GAG
ACC TCT GTC GAA CGG ATT CGA-30), was ligated
between the HindIII and XbaI sites of pUC18 (Invitrogen,
Calsbad, CA, USA). After cleavage with the restriction
enzyme PshAI, the 2.7-kb linear DNA possesses a 2-bp
direct repeat (AG) at both ends (Figure 1B). For the
Linear DNA substrate
ATCCTACAGCTGGAATT….…AAGCTACC ATCCTACAGC
TAGGATGTCGACCTTAA…….TTCGATGGTAGGATGTCG
ATCCTACAGCTGGAATT….…AAGCTACC ATCCTACAGC
TAGGATGTCG ACCTTAA…….TTCGATGGTAGGATGTCG
+
Nuclear extract
….…AAGCTACC ATCCTACAGCATCCTACAGC TGGAATT….…
.……TTCGATGGTAGGATGTCGTAGGATGTCG ACCTTAA.……
.…….AAGCTACC ATCCTACAGC TGGAATT…….
……. .TTCGATGGTAGGATGTCG ACCTTAA…….
Error-free end joining Microhomology-mediated end joining
End joining with deletions
XcmI site
(CCANNNNNNNNNTGG)
AAGCTACCATCCTACAGC GCTGCTAGAGGATCGAT ATCCTACAGC TGGAATT
TTCGATGGTAGGATGTCG CGACGATC TCC TAGCTA TAGGATGTCG ACCTTAA
Eco47III EcoRV
pUC18PD1/4
A
GTGCCAAGCTTCGAATCCGTTCGACAG  AGGTCTCTAGAGGATCCCCGGGTAC
CACGGTTCGAAGCTTAGGCAAGCTGTC  TCCAGAGATCTCCTAGGGGCCCATG
pUC18-2-bp-
repeat
GTGCCAAGCTTCGAATCCGTTCGACAG  CAGTCTCTAGAGGATCCCCGGGTAC
CACGGTTCGAAGCTTAGGCAAGCTGTC GTCAGAGATCTCCTAGGGGCCCATG
pUC18-3-bp-
repeat
PshAI PshAI BC
Figure 1. DNA substrates of end-joining assays. (A) The plasmid pUC18PD1/4 was digested with Eco47III and EcoRV, resulting in a blunt-ended
linear molecule with a 10-bp direct repeat (ATCCTACAGC) at each end. Deletion of one 10-bp repeat in joined DNA will produce an XcmI
restriction site. This particular restriction site can not be created by other joining reactions. (B) The plasmids pUC18-2-bp-repeat and pUC18-3-bp-
repeat were digested with PshAI, resulting in blunt-ended linear molecules with a 2-bp (AG) or 3-bp (CAG), respectively, direct repeat at each end.
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between the HindIII and XbaI sites of pUC18 was
generated by annealing oligonucleotides 3-bp repeat-F
(50-AGC TTC GAA TCC GTT CGA CAG CAG TCT-30)
and 3-bp repeat-R (50-CTA GAG ACT GCT GTC GAA
CGG ATT CGA-30). After cleavage with the restriction
enzyme PshAI, the 2.7-kb linear DNA carries a 3-bp direct
repeat (CAG) at both ends (Figure 1C).
DNA end-joining assay
The end-joining assay, which evaluates the relative
contribution of MHEJ and NHEJ to DNA end joining,
using nuclear extracts and DNA substrates containing
direct repeats at the ends, was conducted as described (9).
Brieﬂy, linearized DNA substrates were incubated with
nuclear protein extract at 148C for 2h. DNA products
were deproteinized, puriﬁed and separated by electro-
phoresis through 0.6% agarose gels. The intensity of
DNA bands was quantiﬁed by using Kodak Gel Logic 100
Imaging System and Kodak 1D Image Analysis Software.
The overall end-joining eﬃciency was calculated as the
percentage of end-joined product (dimer and multimers)
as a fraction of total DNA in the reaction (monomer,
dimer and multimers). All DNA end-joining experiments
were repeated at least three times.
To study the involvement of DNA ligases I and III in
MHEJ, we also treated nuclear extract from HTD114 cells
(1.6mg total protein) with dilutions of monoclonal anti-
body against ligase I or III (Novus Biologicals, Inc.) for
30min on ice. Nuclear extract was then incubated with
380ng linear DNA at 148C for 1h, and DNA end-joined
products were analyzed with agarose gel electrophoresis.
Quantification of MHEJ
The MHEJ activity of individual protein extract was
determined by two steps. First, a quantitative real-time
PCR assay was used to measure the total amount of ‘head
to tail’ end-joined products, including MHEJ products.
Second, the fraction of end-joined products mediated by
microhomology was determined by PCR ampliﬁcation of
the junction of rejoined ends, followed by XcmI digestion
for DNA substrates with 10-bp repeats or by DNA
sequencing for substrates with 2- and 3-bp repeats. The
MHEJ activity of individual nuclear extracts was calcu-
lated by multiplying the values obtained in these two steps.
Step one. The primers utilized in the quantitative real-
time PCR were designed using the Primer Express
software (Applied Biosystems). One pair of primers
ampliﬁes a DNA fragment containing the rejoined ends.
The sequences of the primers for amplifying the 10-bp-
mediated products are: forward, 50-GCC AGT GCC AAG
CTA CCA TC -30, and reverse, 50-TGG AAT TGT GAG
CGG ATA ACA AT-30. The sequences of the primers for
amplifying the 2- or 3-bp-mediated end-joined products
are: forward, 50-GTT GTA AAA CGA CGG CCA
GTG-30, and reverse, 50-CAG CTA TGA CAT GAT
TAC GAA TTC G-30. As an internal loading control, a
pair of primers were used to amplify a DNA fragment that
is about 70bp away from the junction of rejoined ends.
All DNA in the end-joining reaction, including monomers
and multimers, can be ampliﬁed by this pair of primers,
forward, ATT CAG GCT GCG CAA CTG TT-30, and
reverse, 50-CCC AAC TTA ATC GCC TTG CA-30.A n
aliquot of the end-joined product was ampliﬁed for 40
cycles on a GeneAmp 7900HT Sequence Detection
System. Syber Green dye was used for signal detection.
All analyses were carried out in triplicate, and nontem-
plate controls and dissociation curves were used to ensure
speciﬁc template ampliﬁcation. For each primer pair,
serial dilutions of a control DNA were used to determine a
standard curve, and curves with R
2>0.97 were then used
to determine the DNA levels in individual samples.
Step two. The relative contribution of MHEJ using the
10-bp microhomology was determined by PCR ampliﬁca-
tion of the junction of rejoined ends, followed by XcmI
digestion (9). If joining of the DNA ends is mediated
by the 10-bp microhomology, resulting in an XcmI site
(CCAN9TGG) at the junction, digestion of PCR prod-
ucts ( 600bp) with XcmI would give rise to a 400- and
200-bp fragment. Restriction fragments were separated on
a 1% agarose gel. The intensity of the undigested and
XcmI-digested fragments was quantiﬁed using Kodak Gel
Logic 100 Imaging System and Kodak 1D Image Analysis
Software. The relative contribution of the 10-bp micro-
homology-mediated end-joining of the DNA substrate
was calculated as the percentage of the XcmI-digested
fragments of total PCR products (sum of the undigested
and XcmI-digested fragments).
The relative contribution of MHEJ using the 2- or 3-bp
microhomology was determined by sequencing the junc-
tion of rejoined ends. After PCR ampliﬁcation of the
junction, the PCR products were puriﬁed with the
QIAquick PCR puriﬁcation kit (Qiagen). The puriﬁed
DNA was cloned into the TOPO TA cloning vector
pCR4-TOPO (Invitrogen) according to the manufac-
turer’s recommendations. Individual clones were then
sequenced on a Beckman CEQ8000 DNA sequencer.
RESULTS
We previously established an in vitro assay to evaluate
factors involved in MHEJ pathway by using nuclear
extracts and linear DNA substrates containing 10-bp
repeats at the ends (9). We found that the occurrence of
MHEJ in our experimental setting is determined by the
relative abundance of nuclear proteins. At low DNA/
protein ratios, a Ku-dependent end-joining mechanism
predominated over MHEJ. As the DNA/protein ratio
increased, end-joining shifted toward MHEJ (9). The
present study was conducted to determine the roles of
DNA ligases in MHEJ, by using cell extracts that have
reduced, defective or inactive DNA ligases.
Ligase I is requiredfor 10-bpMHEJ
Using siRNA 121249, we were able to decrease the mRNA
level of ligase I in HTD114 cells by 5-fold, as compared
with a nonsilencing control siRNA (Figure 2A).
Meanwhile, this siRNA did not change the mRNA level
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Figure 2. Down-regulation of DNA ligase I leads to reduced MHEJ activity. HTD114 cells were transfected with siRNA oligonucleotides against
DNA ligase I (siRNA 121249). Forty-eight hours after transfection, total RNA and nuclear extracts were prepared. RNA samples were reverse
transcribed to cDNA, followed by real time-PCR, repeated three times for each RNA sample, to determine the expression level of ligase I (A). Data
represent the mean and the SEM. Nuclear extracts were analyzed by immunoblotting with the indicated antibodies (B). (C) End-joining activity
aﬀected by the depletion of Lig1. Linearized pUC18PD1/4 DNA (300ng) was incubated without (lane 1) or with 1mg nuclear protein extracts from
HTD114 transfected with the indicated siRNA oligonucleotides (lanes 2 and 3). The end-joined products were separated by electrophoresis in an
agarose gel and the eﬃciency of end joining was calculated as the percentage of end-joined products (dimer and multimers) in total DNA in the
reaction (monomer, dimer and multimers). (D) A summary of three independent end-joining experiments performed as in C (above). Data represent
the mean and SEM. (E) The amount of end-joined products from individual reactions shown in C (above) was determined, in triplicate, with a
quantitative real time-PCR assay as described in Materials and methods section. The bar represents the mean and the error bar is SEM. (F) End-
joined products from reactions shown in C were PCR ampliﬁed and subsequently digested with XcmI. The relative contribution of 10-bp MHEJ to
DNA end joining was calculated as the percentage of the XcmI-digested fragments in total PCR products (sum of the undigested and XcmI-digested
fragments). (G) Quantiﬁcation of MHEJ activity. The MHEJ activity was calculated by multiplying the amount of end-joined products measured
from (E) with the relative contribution of MHEJ obtained in (F).
Nucleic Acids Research, 2008, Vol. 36, No. 10 3301of DNA ligases III or ligase IV (data not shown). siRNA
121249 also resulted in no detectable ligase I protein
(Figure 2B).
To test whether or not the decrease in DNA ligase I
aﬀects MHEJ, we incubated 300ng linear DNA substrates
containing 10-bp repeats at the ends with 1mg nuclear
extracts (high DNA/protein ratio) prepared from
HTD114 cells that were transfected with siRNA 121249.
As shown in Figure 2C and D, siRNA 121249 signiﬁcantly
decreased the overall end-joining eﬃciency to 40%—a
2.5-fold reduction, of the control (Figure 2D, end-joined
products were the result of the ‘head to tail’, ‘head to
head’ or ‘tail to tail’ end joining).
We performed a 2-step assay to quantify how much of
the decreased end joining was attributed to MHEJ. Since
the 10-bp microhomology only mediates the ‘head to tail’
end joining, we ﬁrst measured the total amount of ‘head to
tail’ end-joined products using quantitative real time PCR.
As shown in Figure 2E, siRNA 121249 decreased the
amount of the ‘head to tail’ end-joined products to about
53% of the control. To determine the fraction of the ‘head
to tail’ end-joined products contributed by MHEJ using
the 10-bp repeat, we PCR ampliﬁed the ligated DNA
products, using primers ﬂanking the end-joined junction,
and subsequently digested the PCR products with XcmI.
Rejoining of DNA substrates catalyzed by MHEJ using
the 10-bp repeat generates an XcmI restriction enzyme site
at the joint. No other joining reaction could create such a
restriction site (9) (Figure 1A). As shown in Figure 2F,
at the 300ng DNA/1mg protein ratio, the relative intensity
of cleaved PCR fragments by XcmI digestion is 98% in
both end-joining reactions. By multiplying the values
obtained from step 1 (Figure 2E) with the relative
contribution of MHEJ in the corresponding end-joining
reaction as shown in Figure 2F, we were able to compare
the relative MHEJ activity between individual extracts. As
shown in Figure 2G, siRNA 121249 decreased the MHEJ
activity to 53% of the control.
GM16096 ﬁbroblast cells, derived from a compound
human heterozygote for ligase I, carry two diﬀerent
missense mutations. The paternal allele showed a substitu-
tion of lysine for glutamic acid, resulting from G-to-A
transition and the maternal allele carried anArg771-to-Trp
mutation, the result of a C-to-T transition (30). Western
blot analysis shows that GM16096 has a signiﬁcantly lower
level of ligase I than normal human ﬁbroblast WI38 cells
(Figure 3A). We extracted nuclear proteins from GM16096
and WI38 and incubated 1mg extract with 500ng DNA
substrate. As shown in Figure 3B, GM16096 had a reduced
overall end-joining eﬃciency. MHEJ using the 10-bp
repeat, the predominant pathway of end joining, was
reduced by 2.5-fold in the extract prepared from GM16096
(Figure 3C), as compared to WI38. Preincubation of 1.6mg
nuclear protein extract prepared from HTD114 cells with
1mg monoclonal antibody raised against ligase I before
initiating the end-joining assay reduced the overall end-
joining eﬃciency by 7-fold, 1% versus 7% in the control
(Figure 3D), and the MHEJ activity by about 5-fold, as
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Figure 3. Mutation in the ligase I gene results in decreased MHEJ. (A) Western blot analysis with the antibody against DNA ligase I. GM16096 cells
are primary human ﬁbroblast cells that carry two diﬀerent missense mutations in the ligase I gene. WI38 cells are primary normal human ﬁbroblasts.
(B) End-joining activities. End-joining assays were carried out using 1mg nuclear extract prepared from GM16096 or WI38 ﬁbroblast cells.
(C) Quantiﬁcation of MHEJ activity. (D) Inhibition of end-joining by anti-Ligase 1 antibodies. Nuclear extract from HTD114 cells (1.6mg total
protein) was incubated for 30min on ice with 1mg antibody against human DNA ligase I, then incubated with 400ng linear DNA at 148C. After 1h
incubation, DNA products were analyzed by agarose gel electrophoresis. (E) Quantiﬁcation of MHEJ aﬀected by anti-ligase 1 antibodies.
3302 Nucleic Acids Research, 2008, Vol. 36, No. 10compared to the control, (Figure 3E). Taken together,
these data clearly demonstrate that DNA ligase I is
required for the 10-bp repeat-mediated end joining.
DNA ligase IIIis also required in10-bpMHEJ
siRNA 121668, which targets against DNA ligase III,
signiﬁcantly reduced the mRNA level and the protein level
of ligase III (Figure 4A and B). At high DNA/protein
(300ng DNA/1mg protein) ratio, DNA end-joining
activity was signiﬁcantly decreased in the nuclear extract
prepared from cells treated with siRNA 121668 (Figure 4C
and D), indicating that reduction in ligase III compromises
the end-joining activity. Further quantiﬁcation of the
10-bp repeat-mediated MHEJ revealed that reduction in
ligase III resulted in decreased MHEJ (Figure 4E),
suggesting that the decrease in overall end-joining eﬃ-
ciency was caused by a decrease in MHEJ.
To substantiate the above ﬁnding, we preincubated
1.6mg nuclear protein extract prepared from HTD114 cells
with a monoclonal antibody raised against ligase III
before initiating the end-joining assay. While the addition
of 1mg anti-ligase III antibody had no eﬀect on the end-
joining eﬃciency, addition of 4mg antibody resulted in
a 3.5-fold reduction, 2% versus 7% in the control, in
the end-joining eﬃciency (Figure 5A). Addition of 4mg
antibody against mouse exonuclease 1, on the other hand,
did not aﬀect the end-joining eﬃciency. XcmI digestion of
PCR products of joined DNA showed that the addition
of 4mg ligase III antibody reduced the relative activity of
MHEJ using the 10-bp repeat, 73% versus 90% in control
(Figure 5B). Together with the result of quantitative real-
time PCR ampliﬁcation of end-joined products, these data
indicate that application of 4mg anti-ligase III antibody
caused a 5-fold decrease in 10-bp repeat-mediated MHEJ
(Figure 5C). Collectively, these data demonstrate that
DNA ligase III is required in MHEJ.
DNA ligase IV isnot requiredin 10-bpMHEJ but
facilitates Ku-dependent NHEJ
By using siRNA 121372 that targets ligase IV, we
were able to reduce the expression of ligase IV at the
mRNA level and at the protein level in HTD114 cells
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Figure 4. Down-regulation of DNA ligase III results in decreased MHEJ activity. HTD114 cells were transfected with nontargeted siRNA (control)
or siRNA oligonucleotides against ligase III (siRNA 121668). Forty-eight hours after transfection, total RNA and nuclear extracts were prepared.
Expression of ligase III at mRNA level and protein level was determined by quantitative real time-PCR (A) and by immunoblotting analysis (B),
respectively. (C) End-joining activity aﬀected by the reduction of ligase III. Linearized pUC18PD1/4 DNA (300ng) was incubated with 1mg nuclear
protein extracts from HTD114 transfected with nontargeted siRNA (lane 1) or the ligase III siRNA 121668 (lane 2). (D) A summary of three
independent end-joining reactions as performed in (C). (E) Quantiﬁcation of MHEJ.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3303(Figure 6A and B). Incubation of 300ng DNA subs-
trate with 1mg nuclear extract isolated from siRNA
121372-transfected HTD114 cells showed that knock-
down of ligase IV slightly increased the MHEJ activity
(Figure 6C–E).
We also isolated nuclear extract from human ﬁbroblast
cells, GM16088, which harbor an Arg278 to His substitu-
tion in the ligase IV gene product, leading to a decreased
level of ligase IV proteins (Figure 7A). The Arg278 residue
is located within a highly conserved motif encompassing
the active site, and the substitution was shown to signi-
ﬁcantly impair ligase IV function (31). Interestingly, end-
joining assay showed that the nuclear extract (1mg) from
GM16088 cells has a 2-fold greater eﬃciency than that
from WI38 cells to ligate DNA substrates (500ng), 10 and
5%, respectively (Figure 7B). XcmI digestion of PCR
products of joined DNA revealed that the MHEJ pathway
mediated by the 10-bp repeat was more dominant in
GM16088 than in WI38, 100% versus 91% (Figure 7C).
Furthermore, the overall MHEJ activity in the nuclear
extract of ligase IV-deﬁcient GM16088 cells was measured
to be 1.8-fold greater than that of WI38 cells (Figure 7D).
Thus, two lines of evidence implicated DNA ligase IV in
the negative regulation of the MHEJ pathway.
DNA ligase IV is known to play an important role in
DNA-PKcs/Ku-dependent NHEJ. Therefore, it is not
unexpected that a decrease in ligase IV expression greatly
decreased the Ku-dependent end-joining activity
(Figure 6F), which was quantiﬁed by using our DNA
end-joining at a low DNA/protein ratio (9). However, it is
worth noting that when the function of ligase IV is
compromised, MHEJ activity is increased (Figures 6
and 7). We can conclude that while DNA ligase IV may
facilitate Ku-dependent end joining, it is not required in
MHEJ.
Roles ofDNA ligases I, IIIand IV in2- and 3-bpMHEJ
The results presented earlier showed that DNA ligases I
and III, but not ligase IV, are required in 10-bp
microhomology-mediated end joining. We further investi-
gated their involvement in DNA end joining mediated by
shorter repeat sequences, i.e. 2- or 3-bp repeats. We made
two plasmid constructs and used PshAI to obtain
linearized DNA substrates, which have 2- or 3-bp direct
repeats at the ends (Figure 1B and C). At a high DNA/
protein ratio (300/1ng/mg), with nuclear extracts prepared
from HTD114 cells, DNA substrates with 2- or 3-bp
repeats were not rejoined as eﬃciently as those with the
10-bp repeats (data not shown). With the nuclear extracts
from HTD114 cells in which DNA ligase I were depleted
by siRNA 121249, the eﬃciency of rejoining the substrates
with 2- or 3-bp repeats was decreased, as compared with
the control (Figure 8A and B). A greater decrease was
observed in HTD114 cells treated with siRNA 121668
against ligase III. With the siRNA 121668 treatment, the
eﬃciencies of rejoining the substrates with 2- and 3-bp
repeats were about 49 and 37%, respectively, of the control
(Figure 8A and B). In contrast, the siRNA treatment
against ligase IV (siRNA 121372) had little eﬀect on the
eﬃciencies of rejoining the substrates with 2- and 3-bp
repeats, as compared with the control (Figure 8A and B).
DNA sequencing results of the end-joined junctions,
shown in Table 1, indicated that majority of end-joining
events were mediated by 2- or 3-bp repeats in the controls,
accounting for 63% (12/19) or 62% (13/21), respectively,
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Figure 5. Requirement of DNA ligase III in MHEJ. (A) The eﬀect of
anti-ligase III antibodies. Nuclear extract from HTD114 cells (1.6mg
total protein) was incubated for 30min on ice with the antibody against
human DNA ligase III, then incubated with 400ng linear DNA at
148C. After 1h incubation, DNA products were analyzed by agarose
gel electrophoresis. (B) PCR products of end-joined products shown in
(A) were digested with XcmI. (C) Quantiﬁcation of MHEJ.
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Figure 6. DNA ligase IV is not required for MHEJ. (A) siRNA-mediated down-regulation of DNA ligase IV in HTD114 cells. Expression of ligase
IV at the mRNA level was determined by quantitative real time-PCR. (B) Expression of ligase IV at the protein level, as determined by the western
blot assay. (C) End-joining activity in nuclear extract with reduced ligase 4. Linearized DNA substrate (300ng) was incubated with 1mg nuclear
protein extracts from HTD114 transfected with nontargeted siRNA (lane 1) or the ligase IV siRNA 121372 (lane 2). (D) A summary of three
independent end-joining reactions as performed in C. (E) Quantiﬁcation of MHEJ. (F) DNA ligase IV is required for the Ku-dependent NHEJ
pathway. End-joining reactions were carried out by incubating 10ng DNA substrates with 8mg nuclear extracts prepared from HTD114 cells treated
with nontargeted siRNA, or siRNA 121372 against ligase IV. PCR products of end-joined products were digested with XcmI. The uncut band
represents the Ku-dependent NHEJ pathway. NHEJ activity was calculated by multiplying the amount of end-joined products measured by real time
PCR with the relative contribution of NHEJ obtained from (A).
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Figure 7. Mutation in the ligase IV gene leads to increased MHEJ. (A) Western blot analysis with the antibody against DNA ligase IV. (B) End-
joining activities. Nuclear extract (1mg) from GM16088 cells, which carry a mutation in ligase IV gene, was incubated with the DNA substrate
(500ng). (C) PCR products of end-joined products shown in (A) were digested with XcmI. (D) Quantiﬁcation of MHEJ.
A B
0
0.2
0.4
0.6
0.8
1
1.2
Control
siRNA
Lig1
siRNA
Lig3
siRNA
Lig4
siRNA
siRNA treatment
E
J
 
p
r
o
d
u
c
t
s
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Control
siRNA
Lig1
siRNA
Lig3
siRNA
Lig4
siRNA
siRNA treatment
E
J
 
p
r
o
d
u
c
t
s
C
0
20
40
60
80
100
120
140
160
Control
siRNA
Lig1
siRNA
Lig3
siRNA
Lig4
siRNA
siRNA treatment
R
e
l
a
t
i
v
e
 
2
 
b
p
 
M
H
E
J
 
a
c
t
i
v
i
t
y
 
(
%
)
0
20
40
60
80
100
120
Control
siRNA
Lig1
siRNA
Lig3
siRNA
Lig4
siRNA
siRNA treatment
R
e
l
a
t
i
v
e
 
3
 
b
p
 
M
H
E
J
 
a
c
t
i
v
i
t
y
 
(
%
) D
Figure 8. The involvement of DNA ligases I, III and IV in 2- and 3-bp MHEJ. End-joining reactions were carried out by incubating 300ng linearized
pUC18-2-bp-repeat (containing a 2-bp, AG repeat at each end, A) or pUC18-3-bp-repeat (containing a 3-bp, CAG repeat at each end, B) with
nuclear extracts (1mg) prepared from HTD114 cells treated with nontargeted siRNA, or siRNA against ligase I (121248), III (121668), or IV
(121372). The amount of end-joined products from individual reactions was determined with a quantitative real time-PCR assay as described in
Materials and methods section. The bar represents the mean end-joining eﬃciency of three independent reactions and the error bar is SEM. The
activity of MHEJ using 2-bp (C) or 3-bp (D) microhomology was determined by multiplying the end joining eﬃciency (A and B) with the fraction of
end-joined products mediated by 2- or 3-bp microhomology (Table 2).
3306 Nucleic Acids Research, 2008, Vol. 36, No. 10of overall end-joining events. Knockdown of ligase I or IV
did not signiﬁcantly change the fraction of such end-
joining events (all P>0.1, chi-squared test, Table 2).
However, knockdown of ligase III, by treatment with
siRNA 121668, resulted in a remarkable decline in the
contribution of 2- and 3-bp MHEJ events, to 26 and 32%,
respectively, of the total end-joining events (both P<0.05,
Table 2).
By multiplying the end-joining eﬃciency (Figure 8A and
B) with the fraction of end-joined products mediated
by 2- or 3-bp microhomology (Table 2), we were able to
determine the eﬀect of siRNA against DNA ligases I, III
or IV on 2- and 3-bp MHEJ. As shown in Figure 8C, while
siRNA 121249, which depletes ligase I, decreased the
activity of 2-bp MHEJ to 88% of the control, it reduced
the activity of 3-bp MHEJ to 54% of the control, sug-
gesting that DNA ligase I plays a more important role in
3-bp MHEJ than in 2-bp MHEJ. The siRNA 121668,
which reduces ligase III, had a greater inhibitory eﬀect on
2- and 3-bp MHEJ than siRNA 121249. The activities of
Table 1. Sequences of junctions of end-joined products
a
DNA substrates siRNA treatments No of clones Sequence change Sequence
b Note
pUC18-2bp-repeat
Non-silencing
control siRNA
1P R
c cttcgaatccgttcgacag
naggtctctagaggatccc
12  2 cttcgaatccgttcgacag
nAGgtctctagaggatccc MHEJ
2  1 cttcgaatccgttcgacag
nAggtctctagaggatccc
2  26 tcgaatccGTTCGACAG
nAGGT......AGGATCCccgg MHEJ
1  47 aatccgtTCGACAG
nAGGT......AATTCGTaatcatg MHEJ
1  7 cttcgaatccgttcgaCAG
nAGGTctctagaggatccc
Lig1 siRNA
7P R
c cttcgaatccgttcgacag
naggtctctagaggatccc
15  2 cttcgaatccgttcgacag
nAGgtctctagaggatccc MHEJ
Lig3 siRNA
10 PR
c cttcgaatccgttcgacag
naggtctctagaggatccc
6  2 cttcgaatccgttcgacag
nAGgtctctagaggatccc MHEJ
1  10 cttcgaatccgttcGACAG
nAGGTCtctagaggatccc MHEJ
2  1 cttcgaatccgttcgacag
nAggtctctagaggatccc
1  47 caagcTTCGA......ACAG
nAGGT......CCGAGctcga
1  47 aatccgtTCGACAG
nAGGT......AATTCGTaatcatg MHEJ
1  13 cttcgaatccgttcgacag
nAGGTCTCTAGAGGatccc
1  4 cttcgaatccgttcgacag
nAGGTctctagaggatccc
Lig4 siRNA
3P R
c cttcgaatccgttcgacag
naggtctctagaggatccc
12  2 cttcgaatccgttcgacag
nAGgtctctagaggatccc MHEJ
1  26 tcgaatccGTTCGACAG
nAGGT......AGGATCCccgg MHEJ
pUC18-3bp-repeat
Non-silencing
control siRNA
5P R
c cttcgaatccgttcgacag
ncagtctctagaggatccc
13  3 cttcgaatccgttcgacag
nCAGtctctagaggatccc MHEJ
2  47 gcttcgaatCCG......ACAG
nCAGT......CTCGAATtcgt MHEJ
1  47 aatccgtTCGACAG
nCAGT......AATTCGTaatcatg MHEJ
Lig1 siRNA
3P R
c cttcgaatccgttcgacag
ncagtctctagaggatccc
9  3 cttcgaatccgttcgacag
nCAGtctctagaggatccc MHEJ
2  1 cttcgaatccgttcgacaG
ncagtctctagaggatccc
2  47 aatccgtTCGACAG
nCAGT......AATTCGTaatcatg MHEJ
1  26 cttcgaatccGTTCGACAG
nCAGT......GGATCCccgg MHEJ
1  47 agcttCGAATCC......ACAG
nCAGT......AGCTcgaattc MHEJ
1  8, +13 cttcgaatccgttcGACAG
nCAGtctctagaggatccc
ATCCACAGCGATA
Lig3 siRNA
11 PR
c cttcgaatccgttcgacag
ncagtctctagaggatccc
7  3 cttcgaatccgttcgacag
nCAGtctctagaggatccc MHEJ
1  1 cttcgaatccgttcgacaG
ncagtctctagaggatccc
2  1 cttcgaatccgttcgacag
nCagtctctagaggatccc
1  2, +2 ttcgaatccgttcgacag
nCagtctctagaggatccc
AG
Lig4 siRNA
9P R
c cttcgaatccgttcgacag
ncagtctctagaggatccc
11  3 cttcgaatccgttcgacag
nCAGtctctagaggatccc MHEJ
aNuclear extract was prepared from HTD114 cells treated with diﬀerent siRNAs.
bThe deleted sequences are indicated by capital letters and the ﬂanking sequences are in lower case. Direct repeats are underlined. The symbol, ‘
n’,
denotes the ends of two joined DNA molecules. Italic letters represent the inserted sequence.
cPR, perfect rejoining.
Nucleic Acids Research, 2008, Vol. 36, No. 10 3307both 2- and 3-bp MHEJ were only about 20% of the
control (Figure 8C and D). Interestingly, siRNA 121372,
which reduces ligase IV, increased the activity of 2-bp
MHEJ to 133% of the control (Figure 8C), consistent with
its eﬀect on 10-bp MHEJ (Figures 6 and 7).
DISCUSSION
The presence of multiple DNA ligases in eukaryotic cells
suggests that these enzymes may each have speciﬁc
functions. This notion is supported by ﬁndings showing
that mammalian cell lines deﬁcient in either DNA ligase I,
III or IV exhibit diﬀerent phenotypes (32). We showed
here that human DNA ligases I and III contribute to
microhomology-mediated end joining (MHEJ). The sup-
porting evidence includes: ﬁrst, siRNA-mediated down-
regulation of DNA ligase I or III in human HTD114 cells
leads to impaired joining of DNA ends mediated by a 10-,
2- or 3-bp microhomology (Figures 2, 4 and 8); second,
GM16096, a cell line derived from a patient with immu-
nodeﬁciency, increased sensitivity to DNA-damaging
agents, and delayed development due to loss of DNA
ligase I function, showed decreased level of MHEJ
(Figure 3); third, treatment of HTD114 nuclear extracts
with antiserum against DNA ligase I or III signiﬁcantly
reduced MHEJ (Figures 3 and 5). We have also shown
that human DNA ligase IV is not required in MHEJ
(Figures 6–8). In addition, reduction of ligase IV signi-
ﬁcantly decreased Ku-dependent NHEJ (Figure 6). Taken
together, these ﬁndings demonstrate that human DNA
ligases I, III and IV each play a diﬀerent role in MHEJ
and Ku-dependent NHEJ, the two end-joining pathways
for DNA DSBs.
DNA ligase I functions in DNA replication to join
Okazaki fragments during lagging-strand DNA synthesis
and in DNA BER to seal single-strand nicks (30). Our
data indicate that DNA ligase I is also involved in end
joining of DNA DSBs, especially in MHEJ. Although
ligase I interacts with several diﬀerent proteins in DNA
replication and BER (17,32), it remains unclear whether or
not it acts alone in MHEJ. It has been shown that the
amino terminus of the DNA ligase I protein has a
proliferating cell nuclear antigen (PCNA)-binding motif
that is required for the loading of the DNA ligase I protein
to replication foci within the nuclei of S-phase cells (20).
Moreover, the PCNA-binding motif is required for the
eﬃcient joining of Okazaki fragments and completion of
long patch BER in cell extract assays (21). Accumulating
evidence suggests that in addition to DNA ligase I, PCNA
interacts with DNA polymerases d " and b replication
factor C (RFC), and a DNA structure-speciﬁc endonu-
clease (FEN-1), and coordinates their activities by forming
complexes that are involved in several DNA metabolic
pathways, including the processing of Okazaki fragments,
and the repair of DNA base damage and single-strand
breaks (SSBs) (32–34). Therefore, it is reasonable to
speculate that PCNA coordinates the involvement of
DNA ligase I and other factors, such as FEN-1, in MHEJ.
Indeed, it has been reported that FEN-1 is required for the
MHEJ pathway (9,35). It is possible that FEN-1 is
responsible for the removal of single-stranded ﬂaps
formed from broken DNA ends during MHEJ, and then
ligase I seals the remaining nick. All these processes are
probably mediated by the protein–protein interaction of
FEN-1 and ligase I with PCNA.
Besides its critical role in the repair of damaged bases
and SSBs (32), evidence from several studies suggests that
DNA ligase III is also involved in DSB repair through an
alternative route of DSB repair that complement the
DNA-PK/XRCC4/ligase IV-dependent NHEJ (35–37). In
line with these ﬁndings, we have shown that DNA ligase
III is required for MHEJ. While ligase III exists in a tight
complex with XRCC1 (23) in BER to repair DNA base
damage and DNA SSBs (38,39), it was also reported that
the Ku-independent end-joining, which may be mediated
by microhomology sequences, required the synapsis
activity of poly(ADP-ribose) polymerase 1 (PARP-1)
and the ligation activity of the XRCC1-DNA ligase III
complex (36), implying that ligase III may also work
together with other factors in MHEJ. However, amongst
DNA ligases, ligase III is unique in having a zinc-ﬁnger
Table 2. Fractions of end-joined products mediated by 2-bp (AG) or 3-bp (CAG) repeats at the ends of substrates
DNA substrates siRNA treatments No. of EJ products
used repeats at the
ends of substrates
No. of total
EJ products
sequenced
Percentage P-value
a
pUC18-2bp-repeat
Non-silencing control siRNA 12 19 63
Lig1 siRNA 15 22 68 0.735
Lig3 siRNA 6 23 26 0.016
Lig4 siRNA 12 16 75 0.452
pUC18-3bp-repeat
Non-silencing control siRNA 13 21 62
Lig1 siRNA 9 19 47 0.356
Lig3 siRNA 7 22 32 0.048
Lig4 siRNA 11 20 55 0.654
aComparisons of the fraction of end joined products mediated by 2- or 3-bp repeats at the ends of substrates in HTD114 nuclear extracts with
siRNA treatments against diﬀerent ligases to the control siRNA were done with contingency tables. Signiﬁcant levels were determined with
chi-squared test.
3308 Nucleic Acids Research, 2008, Vol. 36, No. 10motif at the N-terminus (40), enabling its recruitment to
DNA strand breaks (41). Furthermore, Taylor et al. (42)
reported that the zinc-ﬁnger motif confers upon ligase III
the ability to bind DNA duplexes and stimulates inter-
molecular end joining between DNA duplexes. Therefore,
the possibility that ligase III functions alone in DNA end
joining can not be excluded.
Like DNA ligase III that forms a complex with XRCC1,
DNA ligase IV is tightly associated with XRCC4, upon
which it depends for stability and activity (24,25,43).
Strikingly, ligase IV–XRCC4 complex functions in cou-
pling with Ku heterodimers and DNA PKCS in NHEJ,
but not in other DNA repair pathways (44). In line with
this notion, we here demonstrated that DNA ligase IV
facilitated Ku-dependent end joining (Figure 6), but was
not required for MHEJ (Figures 6 and 7). Furthermore,
when ligase IV was absent, the activity of MHEJ in the
nuclear extract was increased, suggesting that DNA ligase
IV may negatively regulate the MHEJ pathway. It is not
clear how ligase IV inhibits MHEJ. One possibility is that
the Ku-ligase IV–XRCC4-dependent NHEJ pathway,
which is initiated by binding of Ku proteins to DNA
ends, may compete with the MHEJ pathway for binding to
and processing DNA ends (9). Once the DNA ends are
ligated by DNA ligase IV/XRCC4 complex, Ku proteins
presumably become dissociated from DNA, and bind to
other DNA ends to start another round of NHEJ reaction.
Lack of DNA ligase IV would lead to an incomplete NHEJ
reaction in which Ku proteins cannot be released from
DNA ends. Due to lack of competition caused by a
shortage of recycled Ku proteins, DNA ends would have a
greater chance to be exposed to nuclease attack and to be
joined by the alternative MHEJ pathway. In addition,
there is growing evidence showing that DNA ligase IV may
coordinate DNA processing activities that are critical for
both NHEJ and MHEJ. For instance, Ma et al. (45)
showed that there are conserved physical and functional
interactions between DNA polymerase (pol) X family
members (pol m and pol  ) and DNA ligase IV that
coordinate gap-ﬁlling DNA synthesis and DNA ligation in
NHEJ. Notably, in yeast, DNA ligase IV physically and
functionally interacts with Rad27 (FEN-1 in mammalian
cells) to process and join DNA molecules (46). Therefore,
while ligase IV, by interacting with other DNA processing
proteins, may facilitate the Ku-dependent NHEJ pathway,
it may inhibit MHEJ as a consequence of the competition
for components common to both pathways.
Overall, our work showed that human DNA ligase I and
ligase III, which are involved in long patch BER and short
patch BER, respectively, to repair DNA base damage
and SSBs, are also critical for the repair of DSBs by
MHEJ. It should also be noted that the requirement of
ligase I and III seems to vary depending on the length of
microhomology sequences. While a reduction in ligase III
aﬀects MHEJ using both short and long microhomology,
a reduction in ligase I had only slightly aﬀected MHEJ
using 2-bp repeats, though it greatly decreased the MHEJ
using 10-bp repeats. Since the 2- and 3-bp substrates
are much more likely to occur in vivo, ligase III is prob-
ably the primary ligase contributing to MHEJ. This
notion is in accordance with previously published
observations (35–37). Furthermore, our observations also
suggest that DNA ligase I and ligase III may function in
MHEJ through two independent pathways. In keeping up
with this notion, protein partners of DNA ligases I and III,
which are required for their stability, DNA-binding
recruitment and catalytic activity, have never been shown
to overlap. Although little is known about whether or not
other factors may be involved in MHEJ, further studies of
factors involved in the repair of DNA base damage and
SSBs by using our end-joining assay may shed more light
on the mechanisms of DNA DSB repair.
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